Kaisita-M 100/500 Tablet ER is a combination oral antidiabetic medication containing Sitagliptin 100 mg and Metformin 500 mg in an extended-release formulation. It is indicated for the management of type 2 diabetes mellitus in adults, particularly in patients inadequately controlled on diet and exercise alone or on monotherapy. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the incretin system by increasing levels of active incretin hormones, which stimulate insulin release and decrease glucagon secretion in a glucose-dependent manner. Metformin, a biguanide, primarily reduces hepatic glucose production and improves insulin sensitivity, thereby enhancing peripheral glucose uptake and utilization. The extended-release formulation allows for once-daily dosing, improving patient compliance and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Kaisita-M 100/500 Tablet ER should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular blood glucose monitoring. It is contraindicated in patients with renal impairment, metabolic acidosis, or hypersensitivity to its components. Common adverse effects may include gastrointestinal disturbances, headache, and nasopharyngitis. Dose adjustments and monitoring of renal function are recommended to ensure safety and efficacy during therapy.